Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 11

768P - Preliminary results of an open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNA, a DNA repair inhibitor, in addition to PARP inhibitor in patients with relapsed platinum sensitive ovarian cancer already treated with PARPi for at least 6 months (RevoCAN)

Date

21 Oct 2023

Session

Poster session 11

Topics

Tumour Site

Ovarian Cancer

Presenters

Patricia Pautier

Citation

Annals of Oncology (2023) 34 (suppl_2): S507-S542. 10.1016/S0923-7534(23)01937-3

Authors

P. Pautier1, J. Fresnel2, B. You3, F. Bazan4, C. Lebreton5, A. Leary6, D. Chaltiel7

Author affiliations

  • 1 Medicine Dept., Gustave Roussy Cancer Campus, 94805 - VILLEJUIF/FR
  • 2 Medicine Dept., Institut de Cancérologie de l'Ouest, 49055 - Angers/FR
  • 3 Oncology Department, Lyon Sud Hospital Center - HCL, 69495 - Pierre-Bénite/FR
  • 4 Oncology Department, CHRU Besancon - Hopital Jean Minjoz, 25030 - Besancon/FR
  • 5 Medicine Dept., Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), 33000 - Bordeaux/FR
  • 6 Medicine Dept., Institut Gustave Roussy, 94805 - Villejuif/FR
  • 7 Bio Statistics, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 768P

Background

The duration of progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer after response to platinum-based therapy is significantly longer with poly (ADP-ribose) polymerase inhibitors (PARPi). Unfortunately, after initial disease control, resistance to PARPi always occurs at some point. AsiDNA™ is a first-in-class DNA damage repair (DDR) inhibitor designed to prevent the repair of DNA damage in tumor cells. It is an oligonucleotide that mimics DNA double strand breaks, producing a false signal noise which acts as a decoy to disrupt the DDR at the “real” sites of DNA damage. The objective was to reverse acquired resistance to PARPi.

Methods

Patients (pts) who received a PARPi (niraparib, olaparib or rucaparib) in maintenance after platinum-based therapy for at least 6 months and who had an isolated increase of CA125 according to Rustin criteria without RECIST progression were includable. Part A: to assess the feasibility of the association of AsiDNA™ 600 mg in a IV weekly perfusion (higher active dose) + PARPi (last dose taken by the patient before entering the study) Part B: to assess the preliminary efficacy on CA-125 (decrease of 50%). Evaluation was to be done at 10, 15, 20 and 25 pts.

Results

6 patients were included in the dose de-escalation part. No DLT was observed (no related gr 3-4 AE). No more gr 3-4 AE was observed during the treatment of the 10 patients. Among the 10 patients evaluable for efficacy, none had a CA125 response. However, according to RECIST criteria, there were 6 pts with a stable disease, 1 with complete response and 3 with progressive disease. Study was stopped after 12 pts (the company stopped the fabrication of AsiDNA™ for new pts).

Conclusions

AsiDNA in addition to PARPi in pts with biological progression under PARPi is safe, and stabilization (> 6 months) has been observed in 3 pts.

Clinical trial identification

EudraCT 2020-000825-18.

Editorial acknowledgement

Legal entity responsible for the study

Gustave Roussy Cancer campus.

Funding

ONXEO.

Disclosure

P. Pautier: Financial Interests, Personal, Advisory Board, 2015, 2022: PharmaMar; Financial Interests, Institutional, Advisory Board, 2020 : Roche, Clovis; Financial Interests, Institutional, Advisory Board, 2021 : AstraZeneca; Financial Interests, Personal, Advisory Board, 2019-2020: AstraZeneca; Financial Interests, Institutional, Advisory Board: GSK; Financial Interests, Personal, Advisory Board, 2018-2019: Roche; Financial Interests, Institutional, Advisory Board, 2022: MSD; Financial Interests, Personal and Institutional, Research Grant: PharmaMar; Financial Interests, Research Grant: ONXEO. F. Bazan: Financial Interests, Personal, Advisory Board: Daiichi Sankyo, Novartis, Eisai, Menarini; Financial Interests, Personal, Invited Speaker: AstraZeneca. A. Leary: Financial Interests, Personal, Advisory Board: Zentalis; Financial Interests, Personal, Invited Speaker, Educational: GSK, Medscape; Financial Interests, Personal, Writing Engagement, Educational: Onko+; Financial Interests, Institutional, Other, Steering committee: MSD; Financial Interests, Institutional, Advisory Board: GSK, AZ, Clovis, Ability Pharma, MSD, Merck Serono, Apmonia, Blueprint; Financial Interests, Institutional, Invited Speaker, Educational: Kephren publishing; Financial Interests, Institutional, Other, Consultancy: Orion; Financial Interests, Institutional, Invited Speaker: AZ, Clovis; Financial Interests, Personal, Other, Consultancy: GLG; Financial Interests, Institutional, Research Grant, PI translational research: ARCAGY-GINECO, Sanofi, AZ; Financial Interests, Institutional, Funding, CI clinical trial: AZ; Financial Interests, Institutional, Research Grant, Int CI clinical trial: OSE Immuno; Financial Interests, Institutional, Funding, PI clinical trial: Agenus, BMS, Iovance, GSK; Financial Interests, Institutional, Funding, PI 5 clinical trials: Roche; Financial Interests, Institutional, Funding, PI 2 clinical trials: AZ; Financial Interests, Institutional, Funding, PI 3 clinical trials and steering committee: MSD; Non-Financial Interests, Institutional, Other, Academic research project: Owkin, LXRepair; Non-Financial Interests, Personal, Proprietary Information, IDMC member: Clovis; Non-Financial Interests, Personal, Proprietary Information, IDMC chair: Pfizer; Non-Financial Interests, Member: GCIG. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.